NI
Nicox S.A.
NICXF · OTC
$0.30 +0.00% (+$0.00)
Market Cap 24.6M €
P/E Ratio -
Div. Yield -
ROE 438.40%
Bulios Fair Price
$0.2
33.3% downside
Current Price
$0.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NICXF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
33 /100
Expensive P/B 7.20x
P/S 3.12x
EV/FFO N/A
Growth
5 /100
Declining Book val. growth 64.39%
Rev. growth 2.90%
FCF growth N/A
Profitability
22 /100
Weak Op. margin 125.38%
Gross margin 85.88%
FCF margin 0.00%
Quality
4 /100
Poor ROA 91.68%
ROIC 46.51%
Asset turnover 0.32x
Debt
50 /100
Moderate Int. coverage -12.76x
Debt/Equity 5.20x
Net debt/EBITDA -0.35x
Stability
45 /100
Moderate EPS volatility 28.00%
Beta 0.52x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NICXF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Gavin Spencer
Employees
10
Headquarters
Biot
Upcoming events
03 MAR
Earnings
Upcoming earnings report